Advertisement

Topics

Cancer Therapeutics, Inc.TM Company Profile

15:20 EST 16th December 2018 | BioPortfolio

Founded in 1991, Cancer Therapeutics, Inc.TM (CTI) is a biotherapy company that is a leader in activated cell technology for cancer therapy. CTI's laboratory offers access to technologies grouped under the modality of Biotherapy. Biotherapy is based on treatments that enhance the patient's own immune system to attack the invading cancer. Research has shown cancer to be a highly individualized disease. Treatments such as surgery, chemotherapy and radiation work well for some patients, but may not be effective for others. Therefore, Biotherapy has become the fourth method for treating cancer.

Location

210 W. Hansell St.
Thomasville
Georgia
31792
United States of America

Contact

Phone: 229.224.6839
Fax: 229.551.0446
Email: oncology@cancer-therapeutics.com


News Articles [2830 Associated News Articles listed on BioPortfolio]

AdoRx raises $10m funding to discover new cancer therapeutics

UK-based AdoRx Therapeutics, which is focused on discovering new cancer therapeutics, has secured an initial $10m investment round financed by Epidarex Capital and CRT Pioneer Fund (CPF).

Mirati Therapeutics joins Cancer Research UK’s lung cancer programme

Mirati Therapeutics has joined Cancer Research UK’s Stratified Medicine Programme, which aims to develop new treatment options for patients with...Read More... The post Mirati Therapeutics joins Can...

AdoRx raises $10m for new cancer therapeutics

UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.

BriaCell Therapeutics announces positive proof of concept data in treating breast cancer

Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. i...

G1 Therapeutics nets $170mm through public offering

G1 Therapeutics Inc. netted $170mm through the public sale of 3mm common shares at $60. The company develops drugs for cancer, and has three projects in clinical development: trilaciclib (myelopreserv...

G1 Therapeutics nets $195mm through public offering

G1 Therapeutics Inc. netted $195mm through the public sale of 3.45mm common shares (including the overallotment) at $60. The company develops drugs for cancer, and has three projects in clinical devel...

TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push

Five-year-old biotech TP Therapeutics has raised an $80 million mezzanine financing round and promoted its chief medical officer, Athena Countouriotis, to CEO. The San Diego-based biotech, which is de...

Global Cancer Therapeutics Market Expected to Reach $178,863 Million by 2023

     (Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg) The key drivers of the global cancer therapeutics marketare surge in geriatric population and rise in the...

PubMed Articles [6646 Associated PubMed Articles listed on BioPortfolio]

Curing cancer by cancer function.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

Nurse Spiritual Therapeutics Scale: Psychometric Evaluation Among Cancer Patients.

The aim of this study was to translate and validate the Nurse Spiritual Therapeutics Scale (NSTS) among cancer patients in Beijing, China.

Peptide-based targeted therapeutics: Focus on cancer treatment.

Therapeutic peptides are attracting increasing attention for biomedical applications. Peptides present promising opportunities in targeted drug delivery due to their high specificity, selectivity, sma...

A direction to prepare the cancer vaccine.

The vaccine of the cancer can be prepared. This paper presents a direction for preparing the vaccine of cancer by algebraic and geometric study of the cancer cell.

Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications.

Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this ma...

Clinical Trials [8921 Associated Clinical Trials listed on BioPortfolio]

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumorsfor

T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary aim ...

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [2634 Associated Companies listed on BioPortfolio]

Advanced Cancer Therapeutics (ACT)

ACT is a for-profit private company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative ...

Lava Therapeutics

Lava Therapeutics’ proprietary platform is focused on developing next generation γδ T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-onc...

Cancer Therapeutics, Inc.TM

Founded in 1991, Cancer Therapeutics, Inc.TM (CTI) is a biotherapy company that is a leader in activated cell technology for cancer therapy. CTI's laboratory offers access to technologies grouped unde...

BioCancell Therapeutics

BioCancell Therapeutics Inc. is a biopharmaceuticals corporation specializing in the development of Targeted Cancer Therapy for the treatment of numerous types of cancer. The Comp...

Rational Therapeutics, Inc

Who are we?Rational Therapeutics, Inc. (RTI) is a free-standing research laboratory located in Long Beach, CA. Founded in 1993 by Dr. Robert Nagourney, a prominent hematologist/oncologist, Rational Th...

More Information about "Cancer Therapeutics, Inc.TM" on BioPortfolio

We have published hundreds of Cancer Therapeutics, Inc.TM news stories on BioPortfolio along with dozens of Cancer Therapeutics, Inc.TM Clinical Trials and PubMed Articles about Cancer Therapeutics, Inc.TM for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cancer Therapeutics, Inc.TM Companies in our database. You can also find out about relevant Cancer Therapeutics, Inc.TM Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record